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Background: Usher Syndrome is the leading cause of inherited deaf-blindness. It is divided into three subtypes, of
which the most common is Usher type 2, and the USH2A gene accounts for 75-80% of cases. Despite recent
sequencing strategies, in our cohort a significant proportion of individuals with Usher type 2 have just one
heterozygous disease-causing mutation in USH2A, or no convincing disease-causing mutations across nine Usher
genes. The purpose of this study was to improve the molecular diagnosis in these families by screening USH2A for
duplications, heterozygous deletions and a common pathogenic deep intronic variant USH2A: c.7595-2144A>G.
Methods: Forty-nine Usher type 2 or atypical Usher families who had missing mutations (mono-allelic USH2A or no
mutations following Sanger sequencing of nine Usher genes) were screened for duplications/deletions using the
USH2A SALSA MLPA reagent kit (MRC-Holland). Identification of USH2A: c.7595-2144A>G was achieved by Sanger
sequencing. Mutations were confirmed by a combination of reverse transcription PCR using RNA extracted from
nasal epithelial cells or fibroblasts, and by array comparative genomic hybridisation with sequencing across the
genomic breakpoints.
Results: Eight mutations were identified in 23 Usher type 2 families (35%) with one previously identified
heterozygous disease-causing mutation in USH2A. These consisted of five heterozygous deletions, one duplication,
and two heterozygous instances of the pathogenic variant USH2A: c.7595-2144A>G. No variants were found in the
15 Usher type 2 families with no previously identified disease-causing mutations. In 11 atypical families, none of
whom had any previously identified convincing disease-causing mutations, the mutation USH2A: c.7595-2144A>G
was identified in a heterozygous state in one family. All five deletions and the heterozygous duplication we report
here are novel. This is the first time that a duplication in USH2A has been reported as a cause of Usher syndrome.
Conclusions: We found that 8 of 23 (35%) of ‘missing’ mutations in Usher type 2 probands with only a single
heterozygous USH2A mutation detected with Sanger sequencing could be attributed to deletions, duplications or a
pathogenic deep intronic variant. Future mutation detection strategies and genetic counselling will need to take
into account the prevalence of these types of mutations in order to provide a more comprehensive diagnostic
service.
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Usher Syndrome is the leading cause of inherited deaf-
blindness, accounting for 50% of cases. The disorder is
clinically and genetically heterogeneous and is divided
into three clinical subtypes, Usher type 1 (USH1), Usher
type 2 (USH2) and Usher type 3 (USH3). Classification
between subtypes is based upon type of hearing loss and
presence or absence of vestibular dysfunction [1,2]. In
type 1, affected people have profound congenital deaf-
ness, absent vestibular function and prepubertal onset of
retinitis pigmentosa (RP); in type 2 the hearing loss is
moderate to profound (sloping pattern) congenital hear-
ing loss, with normal vestibular function and pre or
post-pubertal onset RP; and in type 3, hearing loss
maybe pre- or post-lingual but progressive in course,
with normal or abnormal vestibular function and often
post-pubertal onset of RP. Individuals who do not have
the usual phenotypes for each of these three subtypes
are classed as atypical. Usher Syndrome is an autosomal
recessive disorder. Previous studies have identified 12
loci and 10 causative genes. The most recently identified
gene is CIB2, which is a rare cause of Usher Type 1 [3].
In addition to these 10 genes, PDZD7 has been impli-
cated as both a modifier and a potential contributor to
digenic inheritance [4].
The prevalence of Usher Syndrome has been estimated
to be 3–6 per 100,000, although recently it has been re-
estimated to have a much higher frequency of 1 in 6,000
[5]. Usher type 2 is the most prevalent form accounting
for more than half of reported cases. There are three
genes underlying USH2: USH2A, GPR98 and DFNB31
(WHRN), with USH2A accounting for 75-80% of cases
[6-8]. The mutational spectrum of USH2A is diverse
and includes nonsense, frameshift, missense and splice-
affecting mutations, as well as deletions and small dupli-
cations [9]. Identifying the correct disease-causing vari-
ant is often confounded by the polymorphic nature of
this gene, and the high frequency of novel mutations as-
sociated with this syndrome. For this reason, missense
variants are assigned a value for their likelihood of caus-
ing disease ranging from Unclassified Variant 1 to 4
(UV1 to UV4). This classification system is based on
frequency in controls, if the variant is novel in Usher
syndrome, segregation with disease, and bioinformatic
analysis of pathogenicity and conservation. UV4 variants
are considered likely pathogenic, UV3 possibly patho-
genic, UV2 possibly polymorphism, UV1 likely poly-
morphism [7,10]. Details of mutations and their ranked
pathogenicity are recorded and revised in the Usher syn-
drome database, an invaluable tool in the molecular
diagnosis of this disorder [9,10].
Despite recent sequencing strategies that have analysed
nine Usher Syndrome genes, and other studies involv-
ing thorough sequencing of USH2A, 8-19% of USH2individuals have just one heterozygous likely disease-
causing mutation in USH2A [6-8], and 13% of USH2
patients have no convincing disease-causing mutations
[7]. Unidentified mutations in USH2 individuals could
lie in the promoter, regulatory regions, and deep in-
tronic areas, all of which are not usually analysed dur-
ing conventional mutation screening. Recently there
has been a report of a pathogenic deep intronic variant
USH2A: c.7595-2144A>G that causes the inclusion of a
152bp pseudoexon in the mRNA transcript, leading to
the frameshift p.(Lys2532Thrfs*56) [11]. This was iden-
tified using investigation of RNA transcripts, under-
pinned by less invasive techniques for obtaining Usher
gene RNA from affected individuals [12,13].
Missing variants might also be attributable to hetero-
zygous deletions and duplications, either those involving
single or multiple exons, or the whole gene. Current in-
vestigations into the genetic basis of Usher syndrome
have focused on Sanger sequencing to detect mutations
[7,8]. It is not possible to robustly detect deletions and
duplications by sequencing alone, as this method is not
sensitive to relative changes in the copy number of
exons. Homozygous whole single exon or multi-exon
deletions can be inferred from consistent PCR non-
amplification, but these are not very common, especially
in the absence of consanguinity. Large duplications and
heterozygous large exonic deletions are in effect ‘invis-
ible’ if the breakpoints are outside of the amplified
region. Previous work has identified such deletions
through haplotype analysis, but to be comprehensive this
requires the individual to carry informative variants in
every exon. More recent methodologies have looked for
deletions and duplications using array comparative gen-
omic hybridization (array CGH) and multiplex ligation
dependent probe amplification (MLPA) [10,14,15]. These
methods have not yet been utilised to detect deletions
and duplications in USH2A in USH2 and atypical indi-
viduals. As this gene is the major genetic contributor to
USH2, and occasionally a cause of atypical Usher, it is
important to screen for deletions and duplications in
USH2A.
In this study we aimed to improve the molecular diagno-
sis of USH2 and atypical Usher by searching for deletions
and duplications in USH2A by MLPA and array CGH, and
by screening for the pathogenic deep intronic variant
USH2A: c.7595-2144A>G. We also sought to develop
methods to analyse splicing variants at the RNA level.
We identified 35% of missing mutations in USH2 fam-
ilies with one previously identified (monoallelic) patho-
genic/UV4/UV3 mutation in USH2A. These variants
include five novel deletions in USH2A and one novel du-
plication. Results were confirmed by array CGH, and
where possible by RNA extracted from nasal epithelial
cells and dermal fibroblasts. This is the first time that
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of splicing variants in Usher Syndrome.
Methods
Patient and control DNAs
Thirty-eight USH2 and 11 atypical families were in-
cluded in this study. Twenty-three of these USH2 fam-
ilies had one pathogenic/UV4/UV3 mutation in USH2A.
The remaining 15 USH2 families and 11 atypical families
had no convincing disease-causing mutations (no muta-
tions above UV2/UV1) in nine Usher genes, MYO7A,
USH1C, CDH23, PCDH15, SANS, USH2A, DFNB31
(WHRN), GPR98, or CLRN1 (only CIB2 not analysed as
CIB2 was described after the completion of this study).
These probands were selected from 121 USH2 and 11
atypical families that were part of a previous mutation
screening programme, the National Collaborative Usher
Study [7]. For genotypes of the forty-nine families
screened see Additional file 1. Clinical data for all atyp-
ical families, and USH2 families with mutations identi-
fied in this study, is given in Additional file 2. Informed
consent was obtained from all participants. For nasal
epithelial brushings and skin punch biopsies, additional
informed consent for these procedures was given. Con-
trol DNA and RNA were obtained from consenting
unrelated healthy individuals. This study adhered to the
provisions of the declaration of Helsinki, and was ap-
proved by the National Research Ethics Committee -
London South East.
Multiplex ligation dependent amplification (MLPA)
The SALSA MLPA FAM labelled reagent kit with probe
mixes P361-A1/ P362-A2 developed by MRC-Holland
(MRC-Holland, Amsterdam, Netherlands), was used to
detect deletions and duplications in the USH2A gene.
Two MLPA probe mixes were required to encompass all
72 exons. Each probe mix contained 15 internal control
probes; nine probes detected non-Usher genes on auto-
somes, four Q-oligonucleotides detected low DNA quan-
tity and two D-oligonucleotides detected incomplete
DNA denaturation. In addition to the 49 USH2 and
atypical families, parents in two further families were in-
cluded to act as positive controls and confirm the valid-
ity of the method. These families were previously
identified to have large homozygous deletions in USH2A
[7]. Family 221 had a homozygous deletion of exon 47,
and family 683 had a homozygous deletion of exon 50–
58. The latter of these was previously published as a
homozygous deletion of USH2A exons 50–55. MLPA
analysis however showed this was in fact a deletion
spanning exons 50–58, which was homozygous in the
proband and heterozygous in both parents. One deletion
control and one healthy control were run per 10 pro-
band DNA samples. Controls without DNA, consistingof TE buffer were used to check for contamination
in reagents.
Reactions were performed as per manufacturer’s in-
structions [16]. Fragment size separation was conducted
on the Applied Biosystems Inc. (ABI) 3730 DNA ana-
lyser with POP7 polymer capillary electrophoresis. Peak
patterns were first evaluated using the raw data check
list and the peak pattern evaluation flow chart available
from MRC Holland (supplied as part of the MLPA gen-
eral protocol). Data that passed peak pattern evaluation
was normalised against negative controls, and dosage
quotients for each probe calculated using Gene Marker
v2.2.0 MLPA analysis software (SoftGenetics, Pennsylvania,
USA) [17]. A probe dosage quotient value of less than
0.8 was considered a deletion, 0.8 to 1.2 normal, greater
than 1.2 a duplication. Samples failed analysis if three or
more of the nine supplied non-Usher gene control
probes were deleted/duplicated.
CGH array
A custom designed CGH-microarray chip (12 × 135 k)
that includes 16 sensorineural hearing loss genes was
used on a high-resolution microarray platform according
to the manufacturer’s recommendations (Nimblegen; Roche
Diagnostics, Basel, Switzerland). The CGH-microarray chip
includes 77,366 probes covering the Usher-related genes
(MYO7A, CDH23, PCDH15, USH1C, USH1G, USH2A,
GPR98, DFNB31, PDZD7, USH3A) and their 10,000-bp 5’
and 3’ regions. The average probe length is 60 bases and
the spacing between starts of probes covering exons and in-
trons is 35 bp. The slides were scanned using InnoScan 900
A (Inopsys, Toulouse, France) and analyzed using Deva
1.2.1 software (Roche NimbleGen, Inc.).
Deletion breakpoint mapping on genomic DNA
Primers were designed to amplify across deletion
breakpoints, based on array CGH results. PCR and se-
quencing was conducted with Biotaq DNA polymerase
(Bioline, London, UK) and Big Dye terminator v1.1 (Ap-
plied Biosystems, Texas, USA). Primer sequences are
available on request.
Nasal epithelial brushings
The lateral inferior turbinate was gently brushed five
times with a 3 mm by 1.8 mm bronchial cytology brush
(Diagmed Ltd, North Yorkshire, UK). Brushes were im-
mediately placed in cell lysis buffer (supplied with
NucleoSpin RNA II, Macherey-Nagel, Duren, Germany).
Skin biopsies and fibroblast cell culture
Punch biopsies were taken from consenting patients
who carried USH2A: c.7595-2144A>G. Biopsied skin was
placed in medium (DMEM glutamax + with 10% fetal
bovine serum, 80 Units/ml of Penicillin and 80 mg/L of
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according to standard procedures. The established fibro-
blast cell lines were trypsinised and passaged weekly as
per standard protocols. For RNA extraction cells in the
log phase of growth were pelleted and resuspended in
cell lysis buffer (supplied with NucleoSpin RNA II,
Macherey-Nagel, Duren, Germany).
RNA extraction and cDNA synthesis
RNA was extracted from fibroblast cell pellets and nasal
epithelial cells with NucleoSpin RNA II (Macherey-
Nagel, Duren, Germany) as per manufacturer’s instruc-
tions. RNA was quantified and assessed for purity using
Nanodrop 1000. For cDNA synthesis 2 μg of RNA was
used for fibroblast samples, and 0.8 μg to 1 μg was used
for nasal samples. cDNA was synthesised using the
Bioline cDNA synthesis kit.
Reverse transcription PCR (RT-PCR)
Genomic contamination was assessed in cDNA using
intron-spanning primers for GAPDH. In addition to this
all RT-PCR primers were designed to be intron-
spanning. When necessary PCR reactions were nested
with internal primers. Primer sequences are available on
request.
Accession numbers
Variants are described as per Human Genome Variation
Society’s recommendations, where +1 is the A in the
ATG translation start codon of USH2A accession num-
ber NM_206933.2.
Results
Identification of large genomic rearrangements in the
USH2A gene
Forty-nine families without convincing biallelic disease-
causing variants were screened for deletions and dupli-
cations in USH2A by MLPA. This group of families
consisted of 23 USH2 families with one previously pub-
lished pathogenic/UV4/UV3 mutation in USH2A, and
15 USH2 and 11 atypical families with only UV2/UV1,
or no variants, across 9 Usher genes (i.e. no convincing
disease-causing variants). For genotypes of all these fam-
ilies see Additional file 1.
No deletions or duplications were found in the 15
USH2 families or in the 11 atypical families with no con-
vincing disease causing mutations. In the 23 families
with a published monoallelic pathogenic/UV4/UV3 mu-
tation in USH2A, seven families were identified with het-
erozygous deletions or duplications. In order to exclude
the possibility that genetic variants beneath the MLPA
oligonucleotides might be causing lack of annealing of
probes to target sequences, these regions were checked
by Sanger sequencing in the seven identified families forvariants. In one family a heterozygous mutation was
found underneath the MLPA probe binding site of the
‘deleted’ target exon, and this was considered to be a
false positive result. The remaining six cases consisted of
five families with heterozygous deletions, and one family
with a heterozygous duplication. The genotypes of these
families are shown in Table 1. Segregation analysis in
each of these families showed that all deletions or dupli-
cations were in trans with a previously identified patho-
genic variant (Figure 1A). For deleted/duplicated MLPA
probe values in these families, see Additional file 3.
The heterozygous duplication of exons 4 to 13 iden-
tified in family 283 is novel. To our knowledge this is
the first time that a duplication of one or more exons in
USH2A has been identified in Usher syndrome. This du-
plication is in trans with p.(Glu767Serfs*21) and segre-
gates with disease in the family. All five identified
deletions were also novel when checked against the
Usher Syndrome mutation database [9]; there have been
no previous reports of deletions of USH2A exon 4, exon
27, exon 40 and exon 70. There is one previously re-
ported deletion of USH2A exons 22–23, however recent
investigations have revised the deletion in that family to
USH2A exons 22–24 [6,9]. The deletion of USH2A
exons 22–23 identified in our study is therefore novel.
Confirmation of USH2A large genomic rearrangements
and breakpoint mapping
To further confirm and study the effects of the identified
deletions, we isolated RNA from nasal epithelial cells
from probands in two families. The proband from family
151 carried a deletion of USH2A exon 22–23 and p.
(Gln1063Serfs*15) in a compound heterozygous state, and
the proband from family 657 carried a deletion of exon 70
and p.(Arg63*) in a compound heterozygous state.
Reverse transcription PCR (RT-PCR) amplification be-
tween USH2A exons 21–26 in the cDNA of the proband
from family 151 produced bands of varying intensity,
shown in Figure 2A. One band of 772 bp was observed
in control cDNA, and corresponded to the non-deletion
allele. A smaller band of 514bp was observed in the pro-
band from family 151 and not on control cDNA; this
was the expected size for a deletion of USH2A exons
22–23. Multiple attempts at sequencing this band failed.
The deletion of USH2A ex22-23 is expected to be in
frame and does not appear to be subject to nonsense
mediated decay. The non-deleted allele in this individual
amplified very faintly, and it is suspected that this allele,
USH2A: p.(Gln1063Serfs*15), could be subject to non-
sense mediated decay or there could be preferential
amplification of the short PCR product from the dele-
tion allele.
In the proband from family 657, repeated RT-PCR at-
tempts to amplify USH2A cDNA across exon 68 to 71
Table 1 Genotypes of probands identified with USH2A deletions/duplications and c.7595-2144A>G p.(Lys2532Thrfs*56)
Family Diagnosis Gene Allele 1a Allele 1 predictedprotein changea Allele 2
b Allele 2 predicted
protein changeb
Pathogenicity
allele 1a
Pathogenicity
allele 2b Ethnicity
c
46 USH2 USH2A c.6862G>T p.(Glu2288*) exon 40 deleted c.7452-68_7594+942del p.(Leu2485Thrfs*25) Pathogenic Pathogenic Caucasian
148 USH2 USH2A c.2299delG p.(Glu767Serfs*21)
exon 27 deleted c.[5299-932_5572+1023del;
5572+1100_5573-1099del] p.(Met1767Valfs*6) Pathogenic Pathogenic Caucasian
151 USH2 USH2A c.3187_3188delCA p.(Gln1063Serfs*15)
exon 22–23 deleted c.4628-15914_4885
+472del
p.
(Ile1544_Gly1629del) Pathogenic Pathogenic Caucasian
309 USH2 USH2A c.2299delG p.(Glu767Serfs*21) exon 4 deleted c.781_784+1375del p.? Pathogenic Pathogenic Caucasian
657 USH2 USH2A c.187C>T p.(Arg63*) exon 70 deleted c.15053-26_15298-708del p.(Leu5019Valfs*77) Pathogenic Pathogenic Caucasian
283 USH2 USH2A c.2299delG p.(Glu767Serfs*21) exons 4–13 duplicated p.? Pathogenic Pathogenic Caucasian
24 USH2 USH2A c.2299delG p.(Glu767Serfs*21) c.7595-2144A>G p.(Lys2532Thrfs*56) Pathogenic Pathogenic Caucasian
707 USH2 USH2A c.2299delG p.(Glu767Serfs*21) c.7595-2144A>G p.(Lys2532Thrfs*56) Pathogenic Pathogenic Caucasian
128
Atypical
Usher
USH2A Unknown Unknown c.7595-2144A>G p.(Lys2532Thrfs*56) Pathogenic
Variants in bold are novel mutations, identified in this study.
a All allele 1 variants have been previously published in these individuals [7].
b All allele 2 variants were identified in this study by USH2A MLPA or sequencing for USH2A: c.7595-2144A>G.
c Caucasian represents UK and European.
Steele-Stallard
et
al.O
rphanet
Journalof
Rare
D
iseases
2013,8:122
Page
5
of
11
http://w
w
w
.ojrd.com
/content/8/1/122
B= USH2
= Atypical 
c.7595-2144A>G /wt
c.7595-2144A>G /c.2299delG
not available
Family 24
c.7595-2144A>G /c.2299delG
not available
c.7595-2144A>G /c.2299delG
not available
Family 707
c.7595-2144A>G /c.2299delG
c.7595-2144A>G /wt
Family 128
c.7595-2144A>G /wt
not available not available
c.7595-2144A>G /wt
not available
exon 40 del /c.6862 G>T 
wt /c.6862 G>T
Family 46A
not available
exon 27 del /c.2299delG 
exon 27 del /wt
Family 148
not available
c.3187_3188delCA /exon 22-23 del 
Family 151
wt /exon 22-23 del 
not available
c.2299delG /exon 4-13 dup  
Family 283
wt /exon 4-13 dup 
c.2299delG /wt c.2299delG /exon 4-13 dup 
not available
c.2299delG /exon 4 del 
Family 309
c.2299delG /wtnot available
exon 70 del /c.187 C>T 
Family 657
not available
wt /c.187 C>T exon 70 del /c.187 C>T
Figure 1 Segregation analysis of families identified with USH2A deletions/duplications and USH2A: c.7595-2144A>G. A. Six families were
found to have deletions/duplications that segregated in trans with a previously identified USH2A pathogenic variant [7]. Variants shown in all
families are in USH2A. All family members were genotyped for USH2A deletions/duplications by MLPA. B. Three families were found to have the
pathogenic variant USH2A: c.7595-2144A>G. All available family members were genotyped for this variant. Family 128 displayed an atypical
phenotype. All three affected siblings were heterozygous for the variant and otherwise were genotypically identical for markers within USH2A
(see Additional file 5). In this family the second USH2A pathogenic mutation is unknown, despite complete sequencing of nine Usher genes,
MLPA analysis for USH2A deletions/duplications and massive parallel sequencing of CIB2 and 60 genes for non-syndromic hearing loss. In addition
the proband has also undergone exome sequencing and no likely disease-causing variants have been found in RP-associated genes. The two
remaining families displayed typical USH2. In family 24 USH2A: c.7595-2144A>G segregated in trans with an already identified USH2A pathogenic
variant [7]. Phase is unknown for family 707. Variants shown in all families are in USH2A.
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during the same reaction. Additional RT-PCR reactions
across USH2A exons 21–26 also amplified in controls, butnot in the proband from family 657 for either USH2A al-
lele. The amount of RNA used for cDNA synthesis was
more than for other probands who did amplify. To assess
772 bp
wild type
514 bp
USH2A
ex.22-23 
deleted
A
B 779 bp USH2A:
c.7595-2144A>G
(contains 152 bp
pseudoexon)
627 bp
wild type
USH2A cDNA 
ex21-26
USH2A cDNA ex40-41
Figure 2 Reverse transcription PCR confirmation of USH2A exon deletions and USH2A: c.7595-2144A>G. A. Reverse Transcription PCR
(RT-PCR) of USH2A exons 21–26 using RNA extracted from nasal epithelial cells as template. The proband from family 151 carries a deletion of
USH2A exons 22–23 in trans with USH2A: p.(Gln1063Serfs*15). In this individual RT-PCR produced a shorter product of 514bp corresponding to a
258bp deletion of USH2A exons 22–23. The other allele in the person amplifies faintly. Amplification on control template produced a band of
772bp, corresponding to wild type. B. Reverse Transcription PCR (RT-PCR) of USH2A exons 40–41 using RNA extracted from fibroblasts as
template. The proband and father in family 24, and the proband in family 128 all carry USH2A: c.7595-2144A>G. This variant is in USH2A intron 40,
and has been previously reported to lead to the inclusion of a 152bp pseudoexon between exon 40–41 resulting in the pathogenic frameshift
p.(Lys2532Thrfs*56). The proband in family 24 also carries this variant in trans with USH2A: p.(Glu767Serfs*21). The other disease-causing allele in
family 128 could not be identified.
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for three other genes were conducted in this individual
using the same template RNA sample. Amplification of
two Usher genes GPR98, WHRN, and of the house-keeping
gene GAPDH produced RT-PCR products of expected size
in the proband from family 657. This suggests that both al-
leles in this individual, exon 70 deleted (which is predicted
to produce the frameshift p.(Leu5019Valfs*77)) and p.
(Arg63*) produce USH2A long isoform transcripts that are
subject to nonsense mediated decay.A custom microarray was used to guide deletion
breakpoint mapping and to confirm presence of dele-
tions where no cDNA was available. Based on the probe
coordinates, it is likely that the four single exon dele-
tions, del E4, E27, E40 and E70 range approximately
from 1.2 to 5 kb in length. The double exon deletion del
E22-23 was found to be approximately 25 kb, and the
duplication dup E4-13 approximately 144 kb in length.
The microarray coordinates were used to design PCR
primers to amplify across the genomic breakpoints of
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in all individuals carrying deletions were smaller than
expected for wild type alleles. Subsequent sequencing of
the PCR products successfully identified the breakpoints
for all five deletions, shown in Table 1. Interestingly the
deletion of USH2A exon 27 in family 148 was found to
comprise two deletions in close proximity (76bp apart)
carried on the same allele USH2A: c.[5299-932_5572+
1023del; 5572+1100_5573-1099del]. The deletion of exon
4 in family 309, was found to be a partial exon deletion
comprising the last 4bp of exon 4 and extending into in-
tron 4, USH2A: c.781_784+1375del. Deletion mapping in
this family is shown in Figure 3. For all other families see
Additional file 4.
Sequencing for USH2A: c.7595-2144A>G p.(Lys2532Thrfs*56)
Of the 23 USH2 families with one pathogenic/UV4/UV3
mutation in USH2A, we identified two USH2 families
with the previously reported pathogenic variant USH2A:
c.7595-2144A>G [11]. The mutation was in trans withfamily 309 proband
deleted allele PCR product
(USH2A: c.781_784+1375del)
USH2A
exon 4
c.781
deletion 
breakpoint
A
USH2A
exon 4
Figure 3 Mapping the deletion breakpoint of USH2A del exon 4 in fam
amplify across the deletion breakpoint on genomic DNA in family 309. Seq
1375del. The segments in red represent the deleted regions, and grey the
breakpoint on genomic DNA in family 309. A smaller band, representing th
control. A larger band amplifies in control, corresponding to the non-delet
deletion, however, the non-deletion allele has not amplified most likely duUSH2A: p.(Glu767Serfs*21) in family 24. In family 707
phase is unknown, but an affected sibling carried the
same two pathogenic mutations (Figure 1B). USH2A:
c.7595-2144A>G was not found in the 15 USH2 families
who had only UV2/UV1 variants.
Interestingly, one atypical family was also identified to
carry USH2A: c.7595-2144A>G. This family consisted of
three affected siblings, all with adult onset hearing loss
(in the fourth decade), diagnosed after the onset of RP
in the mid-teenage years. Vestibular function was nor-
mal in one sibling who has been tested. All three sisters
were heterozygous for the mutation. The other disease-
causing variant in this family is unknown, with no other
pathogenic/UV4/UV3 mutations identified in any Usher
syndrome gene. Recent analysis of CIB2 and 60 genes
causing non-syndromic hearing loss by massive parallel
sequencing did not identify any other pathogenic muta-
tions in this family. The proband has also undergone
exome sequencing and no likely disease-causing variants
have been found in RP-associated genes – data notc.784+1375
B
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ily 309. A. Based on array CGH results PCR primers were designed to
uence analysis identified the exact breakpoint as USH2A: c.781_784+
non-deleted. B. PCR products from amplification across the deletion
e deletion allele, is present in the proband from family 309 but not on
ion allele. The proband from family 309 is heterozygous for the
e to preferential amplification of the shorter PCR product.
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lings showed they share USH2A haplotypes, shown in
Additional file 5.Confirmation of USH2A: c.7595-2144A>G on cDNA
To further study and confirm reported effects of USH2A:
c.7595-2144A>G, we isolated dermal fibroblasts from fam-
ily 24 and the atypical family 128. RT-PCR to amplify
USH2A exons 40–41, was conducted on cDNA synthesised
from these cells. All heterozygous individuals produced a
band of the expected size, 627 bp, plus an additional band
of 779 bp that was not observed in controls, shown in
Figure 2B. Gel extraction and sequencing of the bands
showed the 627 bp fragment corresponded to wild-type se-
quence. The sequence of the 779 bp fragment contained a
152 bp sequence from intron 40, inserted between exon
40–41. This sequence matches that previously reported by
Vaché et al. [11] to be inserted at this point due to USH2A:
c.7595-2144A>G. Our results confirm the findings of this
previous paper regarding the splicing effects and likely
pathogenicity of this deep intronic mutation.Discussion
It is often not possible to identify both pathogenic variants
in USH2A [6-8]. In this study we identified eight muta-
tions in 23 USH2 families (35%) who were known to have
a monoallelic pathogenic/UV4/UV3 mutations in USH2A
detected by Sanger sequencing. These consisted of five
novel heterozygous deletions, one novel duplication in
USH2A, and two cases with the pathogenic variant
USH2A: c.7595-2144A>G p.(Lys2532Thrfs*56). This is the
first time that a duplication in USH2A has been reported
as a cause of Usher syndrome.
Recently the observation of monoallelic mutations in an
Usher gene has been attributed to digenic inheritance,
with the second mutation residing in another Usher gene
[18]. Two families reported by Bonnet et al. [18] were
identified with one pathogenic allele in USH2A, and one
missense variant in an USH1 gene. As these changes in
non-USH2A genes were missense variants and not defin-
itely pathogenic alleles (nonsense, frameshifts or splice
variants) they could in fact be rare benign variants, or dis-
ease modifiers. The true pathogenic mutation could be a
second mutation within the USH2A gene which is not
detected by a simple exon sequencing approach, such
as those we describe here. In our 23 families with a
monoallelic USH2A pathogenic mutation, 35% of second
mutations were missed by the exon sequencing approach.
Indeed, as Abu-Safieh et al. [19] argue in the case of
Bardet-Biedl syndrome, oligogenic inheritance has not
been conclusively substantiated for many diseases. Many
cases of oligogenic inheritance are claimed when multiple
genes are sequenced, and ethnic-specific, usually missensevariants in a second gene are misinterpreted as patho-
genic, as we have found in our previous study [7].
In 15 USH2 families with no pathogenic/UV4/UV3 mu-
tations we did not find any new variants. In five of these
families UV2 variants had already been identified, but
treated as not likely to be disease-causing (see Additional
file 1). It is possible that initial mutation classification of
these variants was too strict, and these variants are more
likely to be disease-causing than their initial assessment.
However due to the polymorphic nature of the Usher
genes, and the lack of a convincing pathogenic second
mutation it is not certain if these are rare polymorphic
variants or pathogenic. They have therefore been given the
cautious pathogenicity ranking of UV2.
Additional explanations for missing variants in families
with zero or one convincing disease-causing mutation
include mutations in introns or promoters that have
pathogenic effects, or mutations in an as yet unidentified
rare Usher gene. Nine Usher genes were analysed in
these individuals, the 10th Usher gene CIB2 was not se-
quenced; however this gene was documented to be a
rare cause of USH1, and not the USH2 phenotype these
families display. These individuals will require further in-
vestigation by exome sequencing to look for new genes,
and/or sequencing of the entire genomic region or RNA
analysis of known Usher genes in order to achieve a
molecular diagnosis. Alternatively some may not have
Usher syndrome per se, but could have disease caused
by mutations in genes which cause non-syndromic deaf-
ness and non-syndromic RP, both of which are very gen-
etically heterogeneous.
In 11 atypical families screened, we identified one
pathogenic mutation USH2A: c.7595-2144A>G in family
128. Previous studies have noted pathogenic mutations
in Usher genes, in patients with atypical clinical features
[8,20-22]. However in the absence of a second mutation
we cannot be sure that USH2A is definitely the cause of
the atypical Usher syndrome in this family. Nevertheless,
despite thorough sequencing of nine Usher genes [7],
USH2A MLPA, and additional screening in the proband
for CIB2, 60 genes causing non-syndromic hearing loss
by massive parallel sequencing, and exome sequencing
we were not able to identify any other obviously patho-
genic mutations in this family. Further investigation of
this family at the RNA level will be conducted in the fu-
ture to help identify the missing variant.
In this study we have established that MLPA and RNA
analysis can detect a significant proportion of mutations
missed by exon sequencing. The nasal ciliated epithelial
collection technique we use requires no anaesthetic, uses
gentle brushing, lasts for a few seconds and has been
very well tolerated by all participants. In addition we
show for the first time that proband-derived fibroblasts
can be used to study splice-affecting mutations in the
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nique has several useful implications. It is possible to
transform fibroblasts into induced pluripotent stem
cells, from which photoreceptors and retinal pigment
epithelial cells can be derived [23]. This has recently
been demonstrated with fibroblasts obtained from indi-
viduals with Usher syndrome and retinitis pigmentosa
[24,25]. These cells could provide a basis for studying
the biological effects of specific mutations and for test-
ing the effects of potential new treatments currently
being developed for Usher syndrome, such as small
molecules or gene therapeutic approaches, in appropri-
ate cells/cell-types [26-28]. This may help produce
more translational relevant results as cells derived from
patients with Usher Syndrome will have an advantage
over current mouse models of USH1, which do not ac-
curately represent the ophthalmic aspects of this dis-
order [29,30].
In our previous Sanger sequencing effort of nine
Usher syndrome genes in 121 USH2 families, we identi-
fied two pathogenic/UV4/UV3 variants in 65% (79/121)
of families, one pathogenic/UV4/UV3 variant in 21%
(26/121) of families and no pathogenic/UV4/UV3 vari-
ants in 13% (16/121) of families. The USH2A MLPA kit
we have used in this study was able to quantitatively de-
tect changes in the copy number of an exon in a further
6 families and is therefore a useful addition in the mo-
lecular diagnosis of USH2. Taking into account all the
new mutations identified and further work, these figures
can be re-calculated for USH2 families. When se-
quenced for 9 Usher Syndrome genes, and screened
for USH2A deletions, duplications and for the patho-
genic variant USH2A: c.7595-2144A>G, 77% (93/121) of
USH2 families have two pathogenic/UV4/UV3 muta-
tions, 11% (13/121) have one pathogenic/UV4/UV3 mu-
tation and 12% (15/121) have no pathogenic/UV4/UV3
variants. Considering just the USH2A gene, 11 families
remain with mono-allelic USH2A mutations and a yet
unidentified second mutation. A further search for in-
tronic mutations, either by RNA analysis looking for ab-
normal splice variants or ‘allelic drop-out’, or high
throughput sequencing of the USH2A genomic region,
may be useful.Conclusions
We found that 8 of 23 (35%) mutations in individuals
with a monoallelic mutation in USH2A can be attributed
to deletions, duplications and a pathogenic deep intronic
variant. Five novel deletions, one novel duplication and a
previously-described intronic pathogenic mutation have
been identified in this study using MLPA, sequencing
and RNA analysis. Future mutation detection strategies
and genetic counselling will need to take into accountthe prevalence of these types of mutations in order to
provide a more comprehensive diagnostic service.
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